No Data
Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $32
Buy Recommendation for Rocket Pharmaceuticals: Promising Potential of RP-L301 in Severe PKD Cases
Top 3 Health Care Stocks That Could Blast Off This Month
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $37
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Major firms rating丨Wedbush: Initiated coverage on Rocket Pharmaceuticals with an "Outperform" rating.
Wedbush initiates coverage of Rocket Pharmaceuticals with an "Outperform" rating and a Target Price of $32. Ongoing pipeline development and internal capacity are expected to support the company's long-term growth potential. (Gelonghui)
